Artelo Biosciences’ (ARTL) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a research note published on Wednesday morning,Benzinga reports. The firm currently has a $5.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a research note on Tuesday, October 1st.

Artelo Biosciences Trading Down 2.8 %

NASDAQ ARTL opened at $1.05 on Wednesday. Artelo Biosciences has a 1-year low of $1.00 and a 1-year high of $1.75. The stock has a 50-day moving average of $1.15 and a 200-day moving average of $1.28. The firm has a market cap of $3.39 million, a PE ratio of -0.37 and a beta of 1.35.

Artelo Biosciences (NASDAQ:ARTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06. As a group, equities research analysts forecast that Artelo Biosciences will post -2.41 earnings per share for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.